Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
Titel:
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
Auteur:
Soussain, C. Choquet, S. Blonski, M. Leclercq, D. Houillier, C. Rezai, K. Bijou, F. Houot, R. Boyle, E. Gressin, R. Nicolas-Virelizier, E. Barrie, M. Moluçon-Chabrot, C. Lelez, M.L. Clavert, A. Coisy, S. Leruez, S. Touitou, V. Cassoux, N. Daniau, M. Ertault de la Bretonnière, M. El Yamani, A. Ghesquières, H. Hoang-Xuan, K.